GENERA BIOSYSTEMS LIMITED (ASX.GBI)

company deregistered today

a loss declaration has been issued and the capital loss can therefore be claimed in the financial year the declaration is issued (this declaration was issued on 23 March 2021)

liquidators Stephen Dixon and Richard Rohrt of Hamilton Murphy appointed today

administrators Stephen Dixon and Richard Rohrt of Hamilton Murphy appointed - first meeting of creditors to be held on 2 June 2020

delisted from the close of trading on Wednesday, 28 August 2019 pursuant to Listing rule 17.15.

we understand this company failed to pay its annual listing fee on due date and ASX has accordingly removed it from the official list

The company has not paid their annual listing fees in respect of the year ending 30 June 2020 but the securities are already suspended from official quotation.

The company lodges its Appendix 4C Quarterly Cash Flow and Business Update.

The company lodges an Appendix 4C Quarterly Cash Flow and Capital Raising Update. Given that Genera has not placed the required amount of shortfall shares by 30 April in order to meet the Minimum Subscription all application monies received under the Entitlements Issue shall be returned to applicants without interest pursuant to the Prospectus. Within the next 4 to 8 weeks Genera currently anticipates undertaking a capital raising via a placement to selected institutional and HNW investors at an issue price of $0.13 per Ordinary Share to raise up to $3.575 million. Proceeds of the placement shall be applied largely to redeem existing Convertible Notes while the Company intends to retain sufficient funds from the Capital Raise to fund ongoing general working capital requirements.

Upon close, the non-renounceable entitlements issue did not meet the minimum subscription level to facilitate the allotment of new shares. Genera is working toward the goal of placing the required amount of shortfall shares by 30 April in order to meet the Minimum Subscription. Should the Minimum Subscription not be met by 30 April all application monies received under the Entitlements Issue shall be retuned to applicants without interest. Up until 3 months post the Closing Date of Entitlements Issue (20 June 2019) the Board of Genera at its sole discretion may place any available shortfall shares to investors. Genera is on track to lodge its accounts for the 6 months to 31 December 2018 within the next 10 Business Days.

$11,365,031 four for five non-renounceable entitlements issue (Entitlements Issue) as announced on 31 January 2019 closed on 20 March 2019. Applications were received under the Entitlements Issue for a total of 1,900,481 fully paid ordinary shares for a total subscription amount received of $243,062. This comprises 1,783,980 entitlement shares and 116,501 additionally subscribed shares. The company gives notice of a shortfall in subscriptions of 86,149,833 shares.

$11,365,031 four for five nonrenounceable entitlements issue (Entitlements Issue) as announced on 31 January 2019 closed on 20 March 2019. Applications were received under the Entitlements Issue for a total of 1,869,712 fully paid ordinary shares for a total subscription amount received of $243,062. This comprises 1,753,211 entitlement shares and 116,501 additionally subscribed shares. The company gives notice of a shortfall in subscriptions of 86,179,833 shares.

The closing date for the non-renounceable entitlement offer will be extended by 3 further business days, to 5.00pm (AEDT) 20 March 2019. The Company anticipates that the Half Year Report will be lodged with ASX on Monday 18 March. The extended closing date of 20 March should provide shareholders sufficient time to consider the contents of the report prior to the Entitlement Offer Close Date.

The closing date for the present non-renounceable entitlement offer will be extended by one further week, to 5.00pm (AEDT) 15 March 2019. The CEO has only just returned from overseas, which impacted the timing for the lodgment of the Company's Half Year Report. The Company anticipates that the Half Year Report will be lodged with ASX late this week. The extended closing date of 15 March should provide shareholders sufficient time to consider the contents of the report.

The company releases a Corporate Update for February 2019.

The entitlement offer prospectus together with the personalised entitlement and acceptance form has today been despatched to eligible shareholders.

The company advises that the closing date for the entitlement offer will be extended by one week such that the offer will now close at 5:00pm (AEDT) on Friday 8 March 2019. The reason for the extension is that the CEO has a series of meetings in the US some of which have been pushed out a week for later this month. The purpose of these meetings is to engage with specialist investors that may be interested in subscribing for shortfall shares that may be available to be placed by the Directors within 3 months of the close of the Offer.

The company lodges its December 2018 Appendix 4C.

The company releases a letter to its optionholders regarding the non-renounceable entitlement offer.

The company releases a letter to its shareholders regarding the non-renounceable entitlement offer.

The company announces a non-renounceable entitlement offer of fully paid ordinary shares. The new shares to be issued pursuant to the Entitlement Offer will rank equally with the Company's existing fully paid ordinary shares. The Entitlement Offer is only open to eligible shareholders, being shareholders whose registered address is in Australia or New Zealand at 7.00pm (AEDT) on Wednesday, 6 February 2019.

The company issues a prospectus which relates to the offer of a 4 to 5 non-renounceable rights issue of new fully paid ordinary shares in the Company at a price of $0.13 per New Share.

The company has received its R&D Tax Incentive rebate for the 2017/2018 financial year amounting to $438,087 which includes an amount payable that was netted off by the ATO on the Company's integrated tax portal account. The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

The company releases the results of its meeting.

The company releases its 2018 CEO AGM Presentation.

The company releases its Appendix 4G and Corporate Governance Statement.

The company lodges its 2018 Annual Report to Shareholders.

The company releases a notice of AGM with explanatory statement and proxy form. The meeting will be held on 14 December 2018 at 11.00AM (AEDT) at Level 22, Tower 5 727 Collins Street, Melbourne VIC 3008.

ASIC has granted an extension of the period of time in which Genera must hold its Annual General Meeting (AGM) for its financial year ended 30 June 2018. Pursuant to the relief granted by ASIC, the latest date on which GBI may hold its AGM has been extended from 30 November 2018 to 14 December 2018.

The company lodges a business update and September 2018 Appendix 4C.

The Company is currently finalising its annual audit and currently aims to lodge its Annual Report with the ASX the week commencing 8 October 2018. The audited accounts and Annual Report are currently being finalised and a short delay will be incurred while final agreements are being put in place with existing Noteholders. The company also intends to lodge a prospectus with ASIC in the week of 15 October to raise up to $11.2M via a 4 for 5 non-renounceable entitlements issue at an Issue Price of $0.13 per new share.

The company lodges its 30 June 2018 Appendix 4E - Preliminary Final Report.

Genera is on track to lodge a prospectus with ASIC the week of 14 September to raise up to $11.2M via a 4 for 5 non-renounceable entitlements issue at an Issue Price of $0.13 per new share. The proposed Entitlements Issue is currently anticipated to close the first week of October and is aimed to strengthen the Company's financial position and support the planned rollout of Genera's test menu operating on the new automated Beckman Coulter system, an expansion of Genera's test development and commercialisation teams and an expansion of the AmpaSand test menu. An error in relation to the interest amounts accrued for the Series B Convertible Notes has been identified. As at 30 June 2018 the total amount outstanding to Series B Convertible Note holders was $7.2m. Genera will lodge its Appendix 4E with ASX pre-market Monday 3 September.

Following a scheduled ASX internal system change affecting the Market Announcements Platform, it has been necessary to re-apply the "˜Suspend' session state. This announcement serves to re-confirm the securities of this entity remain suspended.

The company provides a Business Update and lodges its sJune 2018 Appendix 4C.

The company made a request to ASX that its shares remain in suspension while it prepares and lodges a long form prospectus for a non-renounceable entitlements issue of Ordinary Shares to raise up to $11.2m. Genera continues to engage with a well-credentialed trade-related party in relation to a jurisdictional licensing of PapType for China and potentially other selected markets excluding the Australian, New Zealand, US and Canadian markets. Any completed licensing transaction would involve an upfront license fee payment that may further strengthen Genera's financial position and support the commercial roll-out of Genera's valuable AmpaSand test menu running on the new Beckman Coulter system.

The securities of Genera Biosystems Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of the Company, pending the release of an announcement regarding a capital raising.

The securities of Genera Biosystems Limited will be reinstated to quotation immediately, following the release of an announcement by the Company.

Beckman Coulter Life Sciences and Genera Biosystems Limited have entered into a co-marketing partnership.

The securities of Genera Biosystems Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company.

The suspension of trading in the securities of Genera Biosystems Limited (the "Company") will be lifted immediately, following the release of an announcement by the Company. For further information, please refer to the Company's announcement dated 19 December 2014. Security Code: GBI

Following the Company's request for a trading halt announced Wednesday 10th December 2014 and the Company's requests for a voluntary suspension as announced on Friday 12th December 2014, the Company requests an extension to the voluntary suspension of its securities (GBI) pending the release of an announcement to the market regarding a capital raising

The securities of Genera Biosystems Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. For further details please refer to the Company's request for suspension. Security Code: GBI

The suspension of trading in the securities of Genera Biosystems Limited (the "Company") will be lifted immediately, following the release of an announcement by the Company. Security Code: GBI

Following the Company's request for a voluntary suspension of its securities announced Wednesday 10th July 2013, the Company requests an extension of the voluntary suspension of its securities (GBI) effective immediately pending the execution of documentation for the issuance of convertible notes. In accordance with ASX Listing Rule 17.2, the Company provides the following information: - The suspension will be until the earlier of the release of the announcement or prior to commencement of trading on Wednesday 17th July 2013. - The Company is not aware of any reason why its suspension should not be granted. - The Company is not aware of any further information which is required to inform the market of the voluntary suspension.

The securities of Genera Biosystems Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement. Security Code: GBI

listed entity carried for record purposes only